Kevin (Penghui) Chen is founding partner at Biotrack Capital. Previously, he was a partner at Sequoia Capital China, responsible for healthcare investment. Before Sequoia, Mr. Chen set up the first healthcare fund at Everbright Holdings and served as head of Everbright Healthcare Fund. Mr. Chen has led investments in over 20 leading healthcare companies in China such as BGI, Betta Pharma, Yuwell Medical, Zai Lab, and Amcare Hospital etc. Before Everbright, he was the President, COO & CFO of ShangPharma Corporation between 2008 and 2011 and took the company public at NYSE in 2010. Mr. Chen also worked as research scientist at Ligand Pharmaceuticals in San Diego, California. Mr. Chen holds a bachelor degree in chemistry from Nanjing University, master degree in medicinal chemistry from Tulane University and an MBA from Kellogg School of Management, Northwestern University.